异甘草酸镁联合乙酰半胱氨酸治疗药物性肝损伤患者血清氧化应激指标的改变*

doi:10.3969/j.issn.1672-5069.2020.02.020

摘要/Abstract

摘要： 目的观察应用异甘草酸镁联合乙酰半胱氨酸治疗药物性肝损伤(DILI)患者血清氧化应激指标的变化。方法采用随机数字表法将100例DILI患者分为观察组50例和对照组50例。给予对照组异甘草酸镁治疗,给予观察组异甘草酸镁联合乙酰半胱氨酸治疗,两组患者均连续治疗4周。检测血清丙二醛(MDA)、超氧化物岐化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)、白介素-6(IL-6)和降钙素原(PCT)。结果治疗后,观察组血清总胆红素、天冬氨酸氨基转移酶、丙氨酸氨基转移酶和谷氨酰转肽酶水平分别为(14.2±4.6)μmol/L、(62.9±6.8)U/L、(67.5±6.9)、(54.9±8.9)U/L,显著低于对照组【分别为(21.4±7.3)μmol/L、(90.3±8.4)U/L、(86.4±7.5)U/L、(63.6±6.4),P<0.05】;治疗后,观察组血清MDA水平为(4.8±0.7)μmol/L ,显著低于对照组【(6.2±1.1)μmol/L,P<0.05】,血清SOD和GSH-Px水平分别为(81.5±7.9)U/L和(124.7±9.9)U/L,显著高于对照组【分别为(75.5±8.3)U/L和(92.6±8.7)U/L,P<0.05】,血清IL-6和PCT水平分别为(4.2±0.7)pg/L 和(0.3±0.1)ng/L,显著低于对照组【分别为(6.6±1.2)pg/L和(0.5±0.1)ng/L, P<0.05】。结论联合应用异甘草酸镁和乙酰半胱氨酸治疗DILI患者,近期效果较好,可有效抑制机体炎症反应和氧化应激反应,改善肝功能,值得临床进一步验证。

关键词: 药物性肝损伤, 乙酰半胱氨酸, 异甘草酸镁, 氧化应激, 炎症反应, 治疗

Abstract: Objective The aim of this study was to investigate the efficacy of cetylcysteine combined with magnesium isoglycyrrhizinate in treatment of patients with drug-induced liver injuries (DILI). Methods 100 patients with DILI were randomly divided into observation (n=50) and control group (n=50) in this study. The patients in the control group were treated with magnesium isoglycyrrhizinate, and those in the observation group received acetylcysteine and magnesium isoglycyrrhizinate combination for 4 weeks. Serum malonaldehyde (MDA), superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), interleukin-6 (IL-6) and procalcitonin (PCT) levels were assayed in all the patients. Results At the end on the observation, serum bilirubin, aspartate aminotransferase, alanine aminotransferase and glutamic transpeptidase levels in the combination group were(14.2±4.6)μmol/L,(62.9±6.8)U/L,(67.5±6.9) and (54.9±8.9)U/L, significantly lower than 【(21.4±7.3)μmol/L, (90.3±8.4)U/L, (86.4±7.5)U/L and (63.6±6.4), respectively, P<0.05】 in the control; serum MDA level was (4.8±0.7)μmol/L, much lower than 【(6.2±1.1)μmol/L, P<0.05】, serum SOD and GSH-Px levels were (81.5±7.9)U/L and (124.7±9.9)U/L, significantly higher than 【(75.5±8.3)U/L and (92.6±8.7)U/L, respectively, P<0.05】, serum IL-6 and PCT levels were (4.2±0.7)pg/L and (0.3±0.1)ng/L, significantly lower than 【(6.6±1.2)pg/L and (0.5±0.1)ng/L, respectively, P<0.05】 in the control. Conclusion The combination of magnesium isoglycyrrhizinate and acetylcysteine in treatment of patients with DILI is efficacious for short-term observation, which might be related to the inhibition of inflammatory reaction and oxidative stress.

Key words: Drug-induced liver injury, Acetylcysteine, Magnesium isoglycyrrhizinate, Oxidative stress, Inflammatory reaction, Therapy

王红学, 朱清静, 张玉娟, 毛重山. 异甘草酸镁联合乙酰半胱氨酸治疗药物性肝损伤患者血清氧化应激指标的改变^*[J]. 实用肝脏病杂志, 2020, 23(2): 227-230.

Wang Hongxue, Zhu Qingjing, Zhang Yujuan , et al. Efficacy of cetylcysteine combined with magnesium isoglycyrrhizinate in treatment of patients with drug-induced liver injuries[J]. Journal of Practical Hepatology, 2020, 23(2): 227-230.

参考文献

[1] 刘聪, 王婷婷, 左莉莉, 等. 近3年住院患者DILI状况调查. 实用肝脏病杂志, 2018, 21(4): 639-640.
[2] Borlak J, van Bmmel F, Berg T. N-acetylcysteine and prednisolone treatment improved serum biochemistries in suspected flupirtine cases of severe idiosyncratic liver injury. Genes Dis, 2018, 5(4): 349-357.
[3] Tujios SR, Lee WM. Acute liver failure induced by idiosyncratic reaction to drugs: challenges in diagnosis and therapy. Liver Int, 2018, 38(1): 6-14.
[4] Zhou M, Wang M, Zhong RF, et al. Discovery and structure-activity relationship of auriculatone: a potent hepatoprotective agent against acetaminophen-induced liver injury. Bioorg Med Chem Lett, 2017, 27(16): 3636-3642.
[5] Chiew AL, Isbister GK, Kirby KA, et al. Massive paracetamol overdose: an observational study of the effect of activated charcoal and increased acetylcysteine dose (atom-2). Clin Toxicol (Phila), 2017, 55(10): 1055-1065.
[6] Nabi T, Nabi S, Rafiq N, et al. Role of n-acetylcysteine treatment in non-acetaminophen-induced acute liver failure: a prospective study. Saudi J Gastroenterol, 2017, 23(3): 169-175.
[7] Cuomo G, Borghi V, Giuberti T, et al. What to start with in first line treatment of chronic hepatitis b patients: an italian multicentre observational cohort, hbv-rer study group. Infez Med, 2017, 25(2): 150-157.
[8] 胡红锋. 异甘草酸镁注射液治疗DILI后患者的临床效果及血液生化指标变化. 世界华人消化杂志, 2015, 23(1): 125-128.
[9] 佟欣, 樊华. 双环醇治疗胃癌化疗所致肝损伤患者肝功能指标的变化. 实用肝脏病杂志, 2018, 21(4): 625-626.
[10] Alshammari GM, Balakrishnan A, Chinnasamy T. 2-Hydroxy-4-methoxy benzoic acid attenuates the carbon tetra chloride-induced hepatotoxicity and its lipid abnormalities in rats via anti-inflammatory and antioxidant mechanism. Inflamm Res, 2017, 66(9): 753-763.
[11] 刘立伟,赵新颜. DILI临床与组织病理学特点. 实用肝脏病杂志, 2019, 22(2): 160-163.
[12] Nam EJ, Hayashida K, Aquino RS, et al. Syndecan-1 limits the progression of liver injury and promotes liver repair in acetaminophen-induced liver injury in mice. Hepatology, 2017, 66(5): 1601-1615.
[13] Qu B, Xing R, Wang H, et al. Multiple effects of magnesium isoglycyrrhizinate on the disposition of docetaxel in docetaxel-induced liver injury. Xenobiotica, 2017, 47(4): 290-296.
[14] Tan QY, Hu Q, Zhu SN, et al. Licorice root extract and magnesium isoglycyrrhizinate protect against triptolide-induced hepatotoxicity via up-regulation of the nrf2 pathway. Drug Deliv, 2018, 25(1): 1213-1223.
[15] Wardi J, Ernst O, Lilja A, et al. 3-Aminobenzamide prevents concanavalin a-induced acute hepatitis by an anti-inflammatory and anti-oxidative mechanism. Dig Dis Sci, 2018, 63(12): 3382-3397.
[16] Cho YE, Im EJ, Moon PG, et al. Increased liver-specific proteins in circulating extracellular vesicles as potential biomarkers for drug- and alcohol-induced liver injury. PLoS One, 2017, 12(2): e0172463.
[17] Jiang W, Liu J, Li P, et al. Magnesium isoglycyrrhizinate shows hepatoprotective effects in a cyclophosphamide-induced model of hepatic injury. Oncotarget, 2017, 8(20): 33252-33264.
[18] Alvarez-Sola G, Uriarte I, Latasa MU, et al. Engineered fibroblast growth factor 19 protects from acetaminophen-induced liver injury and stimulates aged liver regeneration in mice. Cell Death Dis, 2017, 8(10): e3083.
[19] Otrubová O, Turecky＇ L, Uličná O, et al. Therapeutic effects of n-acetyl-l-cysteine on liver damage induced by long-term ccl4 administration. Gen Physiol Biophys, 2018, 37(1): 23-31.
[20] Zou X, Wang Y, Peng C, et al. Magnesium isoglycyrrhizinate has hepatoprotective effects in an oxaliplatin-induced model of liver injury. Int J Mol Med, 2018, 42(4): 2020-2030.
[21] Nilsson JLÅ, Blomgren A, Nilsson UJ, et al. N,N'-bis(2-mercaptoethyl)isophthalamide binds electrophilic paracetamol metabolites and prevents paracetamol-induced liver toxicity. Basic Clin Pharmacol Toxicol. 2018,123(5):589-593.

异甘草酸镁联合乙酰半胱氨酸治疗药物性肝损伤患者血清氧化应激指标的改变^*

Efficacy of cetylcysteine combined with magnesium isoglycyrrhizinate in treatment of patients with drug-induced liver injuries

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	温博, 王炳元. Wilson’s病:一个潜在的可治疗的遗传性疾病^*[J]. 实用肝脏病杂志, 2020, 23(2): 156-158.
[2]	黄橘村, 胡东辉, 张建军, 田德英. 慢病毒介导miR-203过表达对酒精性肝病大鼠肝损伤的保护作用及其机制研究^*[J]. 实用肝脏病杂志, 2020, 23(2): 171-174.
[3]	周翠梅, 胡立芬, 李家斌, 储雪琴, 郜玉峰. 思维导图在慢性乙型肝炎患者管理中应用价值研究^*[J]. 实用肝脏病杂志, 2020, 23(2): 187-190.
[4]	张晓伟, 钟蕊. 索磷布韦和维帕他韦联合利巴韦林治疗基因2、3型慢性丙型肝炎患者近期疗效和耐受性观察^*[J]. 实用肝脏病杂志, 2020, 23(2): 191-194.
[5]	贾晨, 张涛, 王浩, 戚凤君. 利拉鲁肽治疗非酒精性脂肪性肝病合并2型糖尿病患者血脂、血管内皮功能和肝纤维化指标的变化^*[J]. 实用肝脏病杂志, 2020, 23(2): 203-206.
[6]	任国亮, 李连生, 刘刚, 丰帆, 刘婧. 热量限制饮食对非酒精性脂肪性肝病患者胰岛素抵抗、血脂和氧化应激指标的影响^*[J]. 实用肝脏病杂志, 2020, 23(2): 219-222.
[7]	李永超, 任红军, 刘磊, 张松. 双重血浆吸附联合血浆置换治疗慢加急性乙型肝炎肝衰竭患者临床疗效研究^*[J]. 实用肝脏病杂志, 2020, 23(2): 236-239.
[8]	贾娇, 王芳, 张波, 武琼. 熊去氧胆酸联合骨化三醇治疗原发性胆汁性肝硬化患者疗效和外周血T淋巴细胞亚群的变化^*[J]. 实用肝脏病杂志, 2020, 23(2): 240-243.
[9]	张惠勇, 吴秀欣, 徐成润. 特利加压素联合前列地尔辅助腹水超滤浓缩回输治疗肝硬化并发难治性腹水患者疗效分析^*[J]. 实用肝脏病杂志, 2020, 23(2): 244-247.
[10]	范建高. 不忘初心,砥励前行[J]. 实用肝脏病杂志, 2020, 23(1): 1-1.
[11]	陈从新, 王莉苹. 应用皮质激素治疗肝衰竭存在什么争议？[J]. 实用肝脏病杂志, 2020, 23(1): 2-3.
[12]	范文瀚, 罗怡平, 李成忠. 糖皮质激素应用于肝衰竭治疗机制及其临床时机的把握[J]. 实用肝脏病杂志, 2020, 23(1): 7-9.
[13]	纪宇欣, 李树臣. 应用糖皮质激素治疗肝衰竭临床疗效研究进展[J]. 实用肝脏病杂志, 2020, 23(1): 10-13.
[14]	李永华, 孙延芬, 王佳佳, 李艳颖, 于收. 恩替卡韦联合苦参素治疗慢性乙型肝炎患者疗效及其对外周血辅助性T淋巴细胞的影响^*[J]. 实用肝脏病杂志, 2020, 23(1): 22-25.
[15]	魏重操, 刘娜, 邢欣, 澹台新兴, 杨倩, 蒋潇洒, 王进海. 多烯磷脂酰胆碱联合二甲双胍治疗非酒精性脂肪性肝病患者疗效和安全性Meta分析[J]. 实用肝脏病杂志, 2020, 23(1): 46-49.